How should I titrate levetiracetam (Keppra) for a patient taking 1000 mg twice daily with a serum concentration of 61 µg/mL?

Levetiracetam Dose Adjustment for Supratherapeutic Level

Do not increase the dose—instead, reduce levetiracetam to 750 mg twice daily and recheck the level in 3–5 days, as a serum concentration of 61 µg/mL is well above the therapeutic range and may increase the risk of adverse effects without additional seizure benefit.

Understanding the Therapeutic Range

• The established therapeutic range for levetiracetam is 6–20 µg/mL for routine seizure control, though some sources extend this to 12–46 µg/mL 1.
• Your patient's level of 61 µg/mL exceeds even the upper limit of the broader range, placing them at increased risk for dose-related adverse effects 1.
• Clinical trials demonstrated that doses of 1,000–3,000 mg/day were effective, with responder rates of 22–33% at 1,000 mg/day, 31–34% at 2,000 mg/day, and 39.8% at 3,000 mg/day 2.
• No consistent evidence shows additional benefit above 3,000 mg/day, and higher doses primarily increase adverse effects rather than efficacy 2, 3.

Why the Level is Elevated

• At the current dose of 1,000 mg twice daily (2,000 mg/day total), the patient should typically achieve levels in the therapeutic range 2, 3.
• A level of 61 µg/mL suggests either reduced clearance (renal impairment, elderly age, drug interactions) or accumulation over time 4, 5.
• Enzyme-inducing antiepileptics (phenytoin, carbamazepine, oxcarbazepine) can lower levetiracetam levels by 20–30%, but your patient's elevated level suggests they are not on these medications 5.
• Age is a major factor: elderly patients (>65 years) have approximately 50% reduced clearance compared to younger adults, leading to higher levels at standard doses 4.

Recommended Dose Reduction Strategy

Immediate action:

• Reduce to 750 mg twice daily (1,500 mg/day total), which represents a 25% dose reduction 3.
• This dose remains within the FDA-approved range and should bring levels into the therapeutic window 3.

Monitoring plan:

• Recheck serum level in 3–5 days after the dose reduction to allow for new steady-state (levetiracetam half-life is approximately 5–7 hours in most patients, reaching steady state in 2–3 days) 1, 6.
• Target a trough level of 12–20 µg/mL for optimal seizure control with minimal adverse effects 1.

If level remains elevated (>30 µg/mL):

• Further reduce to 500 mg twice daily (1,000 mg/day), which is the standard starting dose and remains effective in clinical trials 2, 3.
• Evaluate for renal impairment: calculate creatinine clearance, as levetiracetam is predominantly renally eliminated and requires dose adjustment in renal dysfunction 3.

Adverse Effects to Monitor

• Common dose-related effects include somnolence, dizziness, asthenia, and headache, which increase with higher serum levels 2, 7.
• Neuropsychiatric effects such as behavioral problems, depression, and psychosis are more likely at supratherapeutic levels 2, 7, 8.
• Patients with psychiatric history require particularly close monitoring for mood disturbances when levels are elevated 7, 8.

Critical Pitfall to Avoid

• Do not increase the dose based solely on seizure frequency without checking the level first—the patient may already have excessive drug exposure 2, 3.
• Do not assume therapeutic failure if seizures occur with high levels; instead, consider adding a second antiseizure medication (valproate, lamotrigine, or lacosamide) rather than further increasing levetiracetam 9.
• Routine therapeutic drug monitoring is generally unnecessary for levetiracetam due to its linear pharmacokinetics, but it is valuable in cases of suspected toxicity, breakthrough seizures, or special populations (elderly, renal impairment, critically ill) 7, 4.

When to Consider Alternative Strategies

• If seizures persist despite therapeutic levels (12–46 µg/mL), add adjunctive therapy rather than pushing levetiracetam higher 9.
• If the patient is critically ill or in a neurosurgical ICU, they may have augmented renal clearance requiring higher doses, but your patient's elevated level suggests this is not the case 10, 6.
• If the patient is on enzyme-inducing AEDs (phenytoin, carbamazepine), they may require higher doses to maintain therapeutic levels, but again, the elevated level argues against this 5.